Our Biosimilars and Innovation Pipeline
Within the areas of oncology and auto-immune disorders, Dr. Reddy’s Biologics team is working on developing over ten products, including Dr. Reddy’s Abatacept and novel molecules.
Biosimilar Pipeline
- *In-licensed
Product
Therapeutic Area
Type
Early Development
Pre Clinical
Phase1
Phase3
Under Approval
Denosumab*
Oncology, Osteoporosis
Monoclonal Antibody
Abatacept
Auto- immune, Rheumatoid arthritis
Fc Fusion Protein
Daratumumab*
Oncology
Monoclonal Antibody
DRL-BIO-010
Immuno-oncology, Solid Tumors
Monoclonal Antibody
DRL-BIO-011
Immuno-oncology, Solid Tumors
Monoclonal Antibody
DRL-BIO-012
Auto- immune, IBD
Monoclonal Antibody
DRL-BIO-013
Immuno-oncology
Monoclonal Antibody
DRL-BIO-014
Oncology
Antibody Drug Conjugate
DRL-BIO-015
Oncology
Bispecific
DRL-BIO-016
Haematology
Bispecific
DRL-BIO-017
Oncology
Antibody Drug Conjugate
DRL-BIO-018
Allergy
Monoclonal Antibody
DRL-BIO-019
Oncology
Antibody Drug Conjugate
Novel Biologics Pipeline
- **Co-developed
Product
Therapeutic Area
Type
Early Development
Pre Clinical
Phase1
Phase2
Phase3
Under Approval
Coya 302**
ALS
New Biological Entity
Our Products
Our labs, our scientists, and our research – we are all rooting for a healthier world. Each biosimilar product is a testament to our belief in accessibility for all. We are invested in product innovation in the industry and believe that the best biotech companies are ones that are always thinking ahead.
Shirisha
Clinical Dev.
Amila Anna Shaju
Quality
Yamini Mehrotra
Product Dev.
Sreedhari V
Product Dev.
Tirupati Sarath
Engineering
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.